Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$6.56 -2.2%	$6.15	$4.65 ▼ $10.24	$112.22M	0.26	68,898 shs	38,718 shs
EQ Equillium	$1.74 -4.4%	$0.71	$0.27 ▼ $2.26	$108.30M	1.15	23.50 million shs	1.61 million shs
IOBT IO Biotech	$1.58	$1.74	$0.66 ▼ $2.79	$104.09M	0.44	8.66 million shs	508,907 shs
KZR Kezar Life Sciences	$3.95 -0.5%	$4.24	$3.62 ▼ $9.18	$29.07M	0.65	38,011 shs	12,129 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-2.24%	-4.37%	+11.75%	+21.26%	+8.97%
EQ Equillium	-4.40%	-8.42%	+352.42%	+383.47%	+70.59%
IOBT IO Biotech	0.00%	-9.20%	-25.47%	+14.49%	0.00%
KZR Kezar Life Sciences	-0.50%	-2.71%	-7.93%	-5.28%	-35.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	1.8057 of 5 stars	3.5	2.0	0.0	2.6	0.8	0.0
EQ Equillium	1.3315 of 5 stars	1.0	5.0	0.0	4.4	1.7	0.0
IOBT IO Biotech	3.0681 of 5 stars	3.7	3.0	0.0	2.6	2.5	0.6
KZR Kezar Life Sciences	3.8423 of 5 stars	3.2	0.0	4.6	2.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$16.50	151.52% Upside
EQ Equillium	2.00	Hold	$1.00	-42.53% Downside
IOBT IO Biotech	3.33	Buy	$8.67	448.52% Upside
KZR Kezar Life Sciences	2.33	Hold	$9.00	127.85% Upside

Current Analyst Ratings Breakdown

Latest KZR, COYA, IOBT, and EQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/25/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/12/2025	IOBT IO Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $4.00
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.55M	30.92	N/A	N/A	$1.69 per share	3.88
EQ Equillium	$41.10M	2.52	N/A	N/A	$0.08 per share	21.75
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
KZR Kezar Life Sciences	$7M	4.13	N/A	N/A	$12.53 per share	0.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$14.88M	-$1.24	N/A	N/A	N/A	N/A	-61.05%	-53.61%	11/5/2025 (Estimated)
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-139.56%	-90.56%	11/12/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.58	N/A	N/A	N/A	N/A	-281.82%	-169.29%	11/11/2025 (Estimated)
KZR Kezar Life Sciences	-$83.74M	-$9.69	N/A	N/A	N/A	N/A	-63.51%	-52.13%	11/11/2025 (Estimated)

Latest KZR, COYA, IOBT, and EQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/14/2025	Q2 2025	IOBT IO Biotech	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A
8/13/2025	Q2 2025	KZR Kezar Life Sciences	-$2.15	-$1.87	+$0.28	-$1.87	N/A	N/A
8/12/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	-$0.36	-$0.14	-$0.36	$0.78 million	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	7.43	7.43
EQ Equillium	N/A	1.65	1.65
IOBT IO Biotech	4.22	1.96	1.96
KZR Kezar Life Sciences	0.03	7.29	7.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
EQ Equillium	27.05%
IOBT IO Biotech	54.76%
KZR Kezar Life Sciences	67.90%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
EQ Equillium	31.60%
IOBT IO Biotech	4.80%
KZR Kezar Life Sciences	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
EQ Equillium	40	59.50 million	40.70 million	Not Optionable
IOBT IO Biotech	30	65.88 million	N/A	Not Optionable
KZR Kezar Life Sciences	60	7.32 million	6.56 million	Not Optionable

KZR, COYA, IOBT, and EQ Headlines

Recent News About These Companies

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

August 28 at 4:01 PM | businesswire.com

William Blair Analysts Raise Earnings Estimates for KZR

August 19, 2025 | americanbankingnews.com

William Blair Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)

August 15, 2025 | theglobeandmail.com

Kezar Narrows Loss 37 Percent in Q2

August 13, 2025 | aol.comA

Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)

August 13, 2025 | msn.com

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025 | businesswire.com

Kezar sees hepatitis hold lifted, hints at resurrecting lupus program

July 16, 2025 | fiercebiotech.comF

FDA lifts partial hold on Kezar’s zetomipzomib trial

July 16, 2025 | thepharmaletter.comT

Kezar Life Sciences Says FDA Lifts Clinical Hold

July 16, 2025 | marketwatch.com

Kezar Life Sciences stock gains after FDA lifts partial clinical hold

July 16, 2025 | uk.investing.com

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

July 15, 2025 | businesswire.com

Kezar Life Sciences Inc. Research & Ratings | KZR | Barron's

July 13, 2025 | barrons.com

KZR | Kezar Life Sciences Inc. Stock Overview (U.S.: Nasdaq) - Barron's

June 30, 2025 | barrons.com

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

May 27, 2025 | zacks.com

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | businesswire.com

Kezar toplines small Phase 2a dataset in autoimmune liver disease

March 27, 2025 | endpts.comE

Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo

March 27, 2025 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)

March 26, 2025 | markets.businessinsider.com

Kezar Life Sciences reports topline results from PORTOLA trial

March 26, 2025 | markets.businessinsider.com

Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

March 25, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, COYA, IOBT, and EQ Company Descriptions

Coya Therapeutics NASDAQ:COYA

$6.56 -0.15 (-2.24%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$6.58 +0.03 (+0.38%)

As of 08/29/2025 05:00 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Equillium NASDAQ:EQ

$1.74 -0.08 (-4.40%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.69 -0.05 (-3.10%)

As of 08/29/2025 07:55 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

IO Biotech NASDAQ:IOBT

$1.58 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.58 0.00 (0.00%)

As of 08/29/2025 07:45 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Kezar Life Sciences NASDAQ:KZR

$3.95 -0.02 (-0.48%)

As of 08/29/2025 04:00 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time